Differentiation of Infection in Vaccinated Animals for PPR and FMD
Lead Research Organisation:
THE PIRBRIGHT INSTITUTE
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
Peste des petits ruminants (PPR) is an acute, highly contagious viral disease in sheep and goats. South Asia, Middle East including Turkey and African countries including Morocco are endemic for PPR. The main strategy for disease control is vaccinating sheep and goats with live attenuated PPRV. However there are no DIVA vaccines currently available, preventing the differentiation of infection in vaccinated animals (DIVA) and seromonitoring. FMD is another acute and infectious disease of cloven-hoofed domestic animals for which DIVA vaccines would be of value. Recently we have developed two viral vectored based recombinant FMD DIVA candidate vaccines and the immunogenicity of these vaccines needs to be determined.As wild-type PPRV induces immunosuppression in sheep and goats, we need to determine if the live attenuated PPRV vaccine also induces immunosuppression as this could be a problem if PPRV is used as a vector to deliver multivalent vaccines, or if it is administered with other vaccines. If the vaccine strain does induce transient immunosuppression, further studies are needed to increase understanding of the mechanism of immunosuppression &/or to analyse the immunosuppressive effects.
Planned Impact
unavailable
Organisations
- THE PIRBRIGHT INSTITUTE (Lead Research Organisation)
- University of Glasgow (Collaboration)
- Friedrich Loeffler Institute (Collaboration)
- French Agricultural Research Centre for International Development (Collaboration)
- Tamil Nadu Veterinary and Animal Sciences University (Collaboration)
- Onderstepoort Veterinary Institute (Collaboration)
- Indian Immunologicals Ltd (Collaboration)
- Indian Veterinary Research Institute (Collaboration)
Publications
Banyard A
(2014)
Peste des Petits Ruminants Virus, Eastern Asia
in Emerging Infectious Diseases
Bari FD
(2015)
Prediction and characterization of novel epitopes of serotype A foot-and-mouth disease viruses circulating in East Africa using site-directed mutagenesis.
in The Journal of general virology
Casey M
(2014)
The Role of Animals in Emerging Viral Diseases
Casey-Bryars M
(2018)
Waves of endemic foot-and-mouth disease in eastern Africa suggest feasibility of proactive vaccination approaches
in Nature Ecology & Evolution
Harvey WT
(2016)
Identification of Low- and High-Impact Hemagglutinin Amino Acid Substitutions That Drive Antigenic Drift of Influenza A(H1N1) Viruses.
in PLoS pathogens
Lloyd-Jones K
(2017)
Genetic and antigenic characterization of serotype O FMD viruses from East Africa for the selection of suitable vaccine strain.
in Vaccine
Madhanmohan M
(2013)
Development and evaluation of a real-time reverse transcription-loop-mediated isothermal amplification assay for rapid serotyping of foot-and-mouth disease virus.
in Journal of virological methods
| Description | 1. Two viral vector based FMD vaccines were developed that expressed FMD empty capsids and successfully tested in cattle as pilot studies. The vaccines provide full protection against virulent virus challenge. 2. Two PPR live attenuated DIVA vaccines were produced and tested in goats that provided full protection and could differentiate between vaccination and infection. 3. Inclusion of TLR adjuvants in FMD vaccine will stimulate longer duration immunity. 4. IgA antibody test will detect the current/persistent FMD infection. |
| Exploitation Route | These vaccines and DIVA tests are needed to be tested in larger scale in the field. Currently a patent file has been filed for these two PPR DIVA vaccines and tests. Commercialisation licencing agreements are in progress with vaccine industries. |
| Sectors | Agriculture Food and Drink Education Manufacturing including Industrial Biotechology |
| Description | There is potential for commercialisation of these PPR DIVA vaccines and negotiations are initiated. DIVA tests for FMD and PPR are used to differentiate between vaccinated and infected animals. For IDvet NSP DIVA test commercial agreement has been done and Institute is getting royalty for this purpose. Inclusion of TLR adjuvants in FMD vaccine will stimulate longer duration immunity. IgA antibody test will detect the current/persistent infection and IDVET is negotiating with the Institute to commercialise the assay. |
| First Year Of Impact | 2015 |
| Sector | Agriculture, Food and Drink,Education,Manufacturing, including Industrial Biotechology |
| Impact Types | Policy & public services |
| Description | Development and Evaluation of PPR DIVA vaccines |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Citation in other policy documents |
| Impact | Peste des petits ruminants (PPR) is a highly contagious disease, severely affects small ruminants in almost 70 countries in Africa, the Middle East and parts of Asia. It causes USD 1.5 to 2 billion in losses each year in regions that are home to over 80% of the world's sheep and goats and to more than 330 million of the world's poorest people, many of whom depend on them for their livelihoods. The estimated current expenditure on PPR vaccination ranges between USD 270 and 380 million. The annual impact of PPR alone may be valued at between USD 1.45 and 2.1 billion per year. Approximately a third of the global financial burden of PPR is borne by Africa, with a further quarter borne by South Asia. This burden will be removed with the successful eradication of PPR. The undiscounted costs for a fifteen-year Global control Strategy of FAO and OIE are between USD 7.6 and 9.1 billion, with the first five years costing between USD 2.5 and 3.1 billion. (http://www.fao.org/3/a-i4460e.pdf). PPR is currently controlled by vaccination using mainly two live attenuated PPRV vaccines (Nigeria 75/1 and Sungri 96). However, the current vaccines and serological tests are unable to enable Differentiation between naturally Infected and Vaccinated Animals (DIVA). This factor precludes meaningful assessment of vaccine coverage and epidemiological surveillance based on serology, in turn reducing the efficiency of control programmes. Therefore, it is almost impossible to assess the quality and efficacy of existing PPR vaccines without knowing whether positive animals are vaccinated or naturally infected. Unlike rinderpest, where cattle and buffalo were primary hosts, in PPR, new crops (about 30-40%) of lambs and kids are produced every year and are the most susceptible population to bring back new PPR outbreaks6&7. Therefore, it is likely that the cycle of vaccinations and PPR outbreaks will continue until and unless we reach the stage of 80-90% herd immunity. Therefore, development of a marker vaccine and associated DIVA diagnostics will enable the assessment of vaccine efficacy which is essential for any successful vaccination campaign. https://www.pirbright.ac.uk/news/2018/09/pirbright-scientists-run-vaccination-campaign-eradicate-peste-des-petits-ruminant The availability of a recombinant PPRV vaccine with a proven functionality is a prerequisite for the development of novel vaccines that may enable the development of DIVA tools for PPRV diagnostics. In the DBT-BBSRC FADH BB/L004801/1 grant we have rescued Sungri 96 and Nigeria 75/1 vaccine strains. Both the vaccine strains were rescued from respective synthetic c-DNA clones with mutations in the variable part of C terminus of the nucleocapsid (N) gene similar to Dolphin Morbillivirus (DMV) to enable negative marker DIVA vaccines. These two DIVA vaccines along with parental vaccines have been recently tested in a pilot studies in goats. Both the DIVA and parent vaccines provided safety, stability and protection for vaccinated goats whereas the control animals were clinically infected. Patent applications have been made to protect these DIVA vaccines. Agreements are being done with vaccine industries for the licensing and commercialisation. |
| URL | https://www.pirbright.ac.uk/press-releases/2018/09/pirbright-collaboration-provides-tools-peste-des-... |
| Description | Enhancing the duration of Immunity by adding the TLR III adjuvant to the current FMDV vaccine formulation |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Impact | We have demonstrated that addition of TLR III agonist to the existing FMD vaccine formulation, the duration of immunity could be enhanced from 3 to 6 months. There the biannual vaccination practised in endemic country will have no window for the infection. |
| Description | Improvement on FMD and PPR vaccines. Through this partnering award we were able to achive further DBT-BBSRC FADH grant and BBSRC follow on grants whicvh helped us to improve the existing FMD and PPR vaccine. We have now demonstrated that adding TLR adjuvants to the existing vaccine the duration of immunity can be increased upto 6 months. Similarly we have develped PPR DIVA vaccine which can differentiate between infection and vaccination. The Indian Natioanl Goverment and industries are aware of this development so as other through recent FAO/OIE PPR meetings. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | Longer duration immunity for FMD vaccine with TLR adjuvant-Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Contribution to a national consultation/review |
| Description | PPR DIVA Vaccine development . FAO/OIE in the meeting proceedings in December, 2018 recorded the future use of DIVA vaccine in the ongoing PPR eradication programme. This will be useful at least at the end phase of eradication to differentiate between vaccination and infection.As such few industries have contacted us to have the DIVA vaccine strains for commercialisation. Also some of the endemic countries are keen to have the strain for testing the DIVA vaccines in endemic settings. |
| Geographic Reach | Multiple continents/international |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Description | Right FMD vaccine strains for East Africa. We have shown that existing serotype A vaccine is not working for East Africa where as better serotype O vaccines are availabe internationally for use. Government of all the East afican countries are aware about this from our publications. Further hot spots of FMD virus circulation in tanzania has been identifies through a PhD student collaborating to Glasgow University. We have shown that comination of existing oil adjuvant with TLR adjuvants provides better protection. |
| Geographic Reach | Africa |
| Policy Influence Type | Contribution to a national consultation/review |
| URL | https://www.pirbright.ac.uk/press-releases/2017/04/bbsrc-investment |
| Description | An effective vaccination programme for the eradication of foot-and-mouth disease from India |
| Amount | £673,500 (GBP) |
| Funding ID | BB/L004828/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2014 |
| End | 02/2018 |
| Description | Development of multispecies validated serology protocols for complex ecosystems, focused on East Africa, in support of Global PPR eradication |
| Amount | £697,673 (GBP) |
| Funding ID | EP/T015381/1 |
| Organisation | Engineering and Physical Sciences Research Council (EPSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2019 |
| End | 03/2021 |
| Description | Evalution of a stable liquid formulation of the PPR vaccine in sheep and goats |
| Amount | £225,638 (GBP) |
| Funding ID | IAH-R67A1151A1 |
| Organisation | GALVmed |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2020 |
| End | 07/2021 |
| Description | FADH PPR project -Understanding the immune mechanism of host disease resistance and development of marker vaccines and DIVA tests for Peste des Petits Ruminants (PPR) |
| Amount | £351,000 (GBP) |
| Funding ID | BB/L004801/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2014 |
| End | 07/2018 |
| Description | Improving the duration of immunity for FMD vaccine |
| Amount | £201,000 (GBP) |
| Funding ID | BB/N012682/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 04/2016 |
| End | 05/2017 |
| Description | Investigating the feasibility of adapting a direct PCR diagnostics approach to in-field animal testing |
| Amount | £864,356 (GBP) |
| Funding ID | 104623 |
| Organisation | Innovate UK |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 04/2020 |
| Description | Next generation peste-des-petits ruminats (PPR) vaccines that differentiate between infected and vaccinated animals (DIVA) - proof of concept in sheep |
| Amount | £158,845 (GBP) |
| Funding ID | BB/T004096/1 |
| Organisation | Biotechnology and Biological Sciences Research Council (BBSRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 03/2020 |
| End | 03/2021 |
| Title | Appropriate FMD vaccine strains for East Africa and South East Asia and new adjuvants for FMD vaccines that provide longer duration immunity |
| Description | We have identifies appropriate Vaccine strains for Serotyoe O and A for East Africa and for South east Asia which are published now. Additionally we have identified potent and safe adjuvants which has been tested in cattle and provides longer duration immunity. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2014 |
| Provided To Others? | Yes |
| Impact | Governments of East Africa and Regional OIE centre at South East Asia and vaccine producers are aware about the strains and adjuvants. |
| Title | Benifit of addition of TLR III to existing FMD vaccine |
| Description | We have demonstrated that TLR III adjuvants along with existing oil adjuvants provides longer duration immunity. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2018 |
| Provided To Others? | No |
| Impact | This will fulfill the lacuna of short living immunity of FMD inactivated vaccines |
| Title | Facilitated the transfer of molecular technology for the capacity building of the Sokoine University of Agriculture (SUA) Southern African Centre for Infectious Disease Surveillance (SACIDS) peste des petits ruminants (PPR) laboratory. |
| Description | Facilitated the transfer of molecular technology for the capacity building of the Sokoine University of Agriculture (SUA) Southern African Centre for Infectious Disease Surveillance (SACIDS) peste des petits ruminants (PPR) laboratory. |
| Type Of Material | Improvements to research infrastructure |
| Year Produced | 2020 |
| Provided To Others? | Yes |
| Impact | This has increased the capability of detection PPRV from infected samples by qPCR at SACIDS, Tanzania. This will be helpful to analyse samples from all over Africa without sending to Europe. |
| Title | Use of reverse genetics to develop PPR DIVA vaccines |
| Description | Reverse genetics technique has been established for PPR virus in our laboratory. As PPR vaccine is a live attenuated virus, it is not possible to differentiate between vaccinated and infected animals (DIVA) in existing antibody assays. However using reverse genetics technique we have manipulated/mutated residues in the full-length cDNA of virus and rescued the live attenuated vaccine strain which worked as a DIVA vaccine. Using this technique a GFP ( Green fluorescent protein) has been introduced into the virulent PPR virus that helped to follow the virus in the infected goats. Similarly using this technique we have modified the existing live attenuated viruses ( Nigeria 75/1) and Sungri 96/1) in to recombinant marker vaccines that enables to differentiate between infection and vaccination ( DIVA). So we have demonstrated that reverse genetics tool can be used to study the pathogenesis and to develop the marker vaccines. This technique can be adapted for other negative strand viruses to design the DIVA vaccines. |
| Type Of Material | Technology assay or reagent |
| Year Produced | 2015 |
| Provided To Others? | Yes |
| Impact | PPR DIVA vaccine developed that can differentiate between vaccinated and infected animals. This will be helpful to know the efficacy of vaccine by knowing the presence antibodies in animal is due to vaccination or infection. This will reduce the eradication time and will facilitate to declare freedom of diseases as soon as Possible without long waiting period. |
| Description | Adjuvants study-FMD vaccine at Indian Immunologicals |
| Organisation | Indian Immunologicals Ltd |
| Country | India |
| Sector | Private |
| PI Contribution | Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months. |
| Collaborator Contribution | Facilitate the animal experiments at their High containment |
| Impact | Conducted screening of 8 adjuvants with FMD vaccine in cattle and analyse the samples originated from the experiments. 4 selected adjuvants were tested in cattle at the Pirbright Institute and TLR III adjuvant was found as the best one. Under Follow on grant 12 cattle were vaccinated with existing vaccine with oil adjuvant and 12 cattle were vaccinated with oil and TLR III adjuvants. The protective immununity was assessed from the virus neutralizing antibody status. By 6 months post-vaccination only 17% of cattle were having protective antibodies (1:45 dilution) in conventional vaccine group whereas 80% cattle were having protective neutralizing titer (1:45) in TLR adjuvanted group. Therefore it is clear that adding TLR adjuvant one can increase the duration of immunity up to 6 months. |
| Start Year | 2016 |
| Description | Anihwa Call 1 |
| Organisation | French Agricultural Research Centre for International Development |
| Country | France |
| Sector | Private |
| PI Contribution | Developed PCR to detect PPR viral genome in faecal samples for experimentally infected animals. |
| Collaborator Contribution | Developed PCR and antigen ELISA to detect PPR viral genome in faecal samples for field animals including wild life. |
| Impact | Please see publications |
| Start Year | 2013 |
| Description | Anihwa Call 1 |
| Organisation | Friedrich Loeffler Institute |
| Country | Germany |
| Sector | Academic/University |
| PI Contribution | 1. Conducted challenge experiments in goats to study pathogenicity. 2. Developed NGS technology to sequence PPR whole genome. |
| Collaborator Contribution | FLI has conducted transmission study between different species ( Goats, pig, camel). For the first time they showed that pigs are clinically infected by PPR virus. |
| Impact | Joint Publications |
| Start Year | 2013 |
| Description | Epitope prediction for FMD and serosurvey in East Africa |
| Organisation | University of Glasgow |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | 1. Vaccine strain selection for O and A serotype for East Africa. 2. Epitope mapping.3. Analysis of sample collected from Tanzania national parks and domestic animals |
| Collaborator Contribution | 1. Establishing mathematical modelling correlating phenotype to genotype circulating viruses against existing antisera. 2. Sero-survey in wildlife and domesticated animals for epidemiological studies. |
| Impact | 1. Vaccine strains were selected for O and A serotypes for FMD for East Africa. 2. Hotspots were detected for FMD prevalence |
| Start Year | 2016 |
| Description | IVRI, Mukteswar |
| Organisation | Indian Veterinary Research Institute |
| Country | India |
| Sector | Public |
| PI Contribution | 1. DIVA vaccine and DIVA test development. 2.Early pathogenesis study for PPR.3. Sharing of Knowledge 4.Joint publications |
| Collaborator Contribution | Development LAMP technique for PPR |
| Impact | 1. Development of DIVA vaccines and DIVA tests 2. Early pathogenesis study showed that PPR virus first replicates in Tonsils 3. LAM assay developed for PPR |
| Start Year | 2014 |
| Description | Indian Veterinary Research Institute (IVRI), Bareilly |
| Organisation | Indian Veterinary Research Institute |
| Country | India |
| Sector | Public |
| PI Contribution | 1. Development of PPR DIVA vaccine and DIVA tests 2. Early pathogenesis study |
| Collaborator Contribution | Development of Biosensor diagnostic assay for PPR |
| Impact | Joint publications. Sharing of knowledge. |
| Start Year | 2014 |
| Description | TANUVAS, INdia |
| Organisation | Tamil Nadu Veterinary and Animal Sciences University |
| Country | India |
| Sector | Academic/University |
| PI Contribution | 1. Development of DIVA vaccine and DIVA test. 2. Early pathogenesis study.3 Contributed to Transcriptome analysis carried out by TANUVAS |
| Collaborator Contribution | Transcriptome study for disease resistance in different breed of goats, sheep and large ruminants |
| Impact | 1.Development of DIVA vaccine.2. Development of DIVA tests 3. Early pathogenesis study showed that Virus first replicate in tonsils.4. High basal level of SLAM is present in large ruminants in comparison to small ruminants and may be therefore large ruminants are more resistant to the PPR. |
| Start Year | 2014 |
| Description | Vaccine strain selction |
| Organisation | Onderstepoort Veterinary Institute |
| Country | South Africa |
| Sector | Academic/University |
| PI Contribution | 1. Vaccine strain selection for serotype O and A |
| Collaborator Contribution | Vaccine strain selection for serotype SAT1 and SAT2 |
| Impact | Vaccine strain for FMD serotype O and A were selected. |
| Start Year | 2012 |
| Title | Development salivary IgA antibody assay for O,A and Asia1 to detect current FMD infection in field |
| Description | Development salivary IgA antibody assay for O,A and Asia1 to detect current FMD infection in cattle. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2015 |
| Licensed | No |
| Impact | Development salivary IgA antibody assay for O,A and Asia1 to detect current FMD infection/persistence in cattle. |
| Title | Develpment of PPR DIVA Vaccines and DIVA tests |
| Description | Manipulating the genome live attenuated existing PPR vaccine we have developed DIVA vaccines and DIVA tests for PPR that can differentiate between infection and vaccination. This will facilitate the eradication at least at the last phase of eradication. |
| IP Reference | |
| Protection | Copyrighted (e.g. software) |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | PPR DIVA vaccines can differentiate between infection and vaccination that will facilitate the eradication at least at the last phase of eradication programme. |
| Title | NSP and SP FMD antibody tests |
| Description | We have validated NSP DIVA tests with FMD vaccinated/infected carrier animals and field sample for an industry. The assays are now in market and Institute is receiving royalty for the sale. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2015 |
| Licensed | Commercial In Confidence |
| Impact | Due to this validation work now at least two international companies are there for sailing FMD diagnostic assay. This facilitate wide distribution of the kits worldwide. |
| Title | PPR DIVA vaccine |
| Description | We ahve developed two PPR live attenuated DIVA vaccines that can differentiate between vaccinated and infected animals. |
| IP Reference | PCT/GB2019/053641,WO2020128496 |
| Protection | Patent application published |
| Year Protection Granted | 2020 |
| Licensed | Commercial In Confidence |
| Impact | Till date there is no PPR vaccine avalable that can differentiate between vaccination and infection. This causes a huge issue on eradication of the didease and declare freedom from the disease. Therefore our newly develped chimeric live attenauted PPR vaccine and DIVA tests can differentiate between vaccination and infection which is a great achievement for ongoing PPR eradication. Please see detail from the below web. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020128496 |
| Title | TLR II adjuvant can stimulate longer duration of immunity for FMD vaccine. |
| Description | We have shown that TLR II adjuvant when added to the conventional vaccine, it stimulate longer duration immunity, at least up to 6 months. |
| IP Reference | |
| Protection | Protection not required |
| Year Protection Granted | 2016 |
| Licensed | No |
| Impact | Provision of longer duration immunity up to 6 months will help in biannual vaccination control policy. When vaccine provides less than 6 months immunity in biannual vaccination programme, there is always a window for infection. |
| Description | BBSRC Impact case study |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Trainings, workshops and awareness provided on FMD among farmers at Arusha, Tanzania. |
| Year(s) Of Engagement Activity | 2012 |
| URL | https://bbsrc.ukri.org/documents/foot-and-mouth-in-africa-pdf/ |
| Description | Delivered a lead talk at Indian Association of Vetrinary Microbiology and Immunology ( IAVMI) at IVRI, Bareilly on PPR and FMD control by vaccination- February 6-7th, 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Delivered a lead talk at Indian Association of Vetrinary Microbiology and Immunology ( IAVMI) at IVRI, Bareilly on PPR and FMD control by vaccination- February 6-7th, 2020. Further attended the panel meeting with FMD vaccine producers and FMD scientists at PDFMD and IVRI Bangalore to recommend Govt of India for the future control of FMD. Suggested boosting of the first dose FMDV vaccinated animals which will stimulate the immunity up to the second biannual vaccination to avoid any window for infection. |
| Year(s) Of Engagement Activity | 2020 |
| Description | Delivered a lead talk on FMD vaccine and chaired a scientific session at Indian Veterinary Association at New Delhi ( 25.7.19-28.07.19) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Delivered a lead talk on FMD vaccine and chaired a scientific session at Indian Veterinary Association at New Delhi ( 25.7.19-28.07.19). |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.indianveterinaryassociation.in/wp-content/uploads/2019/07/... |
| Description | Delivered a talk on PPR DIVA vaccine at EU Epizone meeting in Berlin-25.8.19-28-08.19 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Delivered a talk on PPR DIVA vaccine at EU Epizone meeting in Berlin-25.8.19-28-08.19 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Delivered an invited talk on Epidemiology of PPR at wildlife Arusha, Tanzania - 22.10.10-26.10.19 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | Delivered an invited talk on PPR epidemiology at wildlife Arusha, Tanzania - 22.10.10-26.10.19 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Delivered invited talks at Greece veterinary association |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Professional Practitioners |
| Results and Impact | Greece veterinary authority invited PI to delivered a talk on PPR threat to Greece from Turkey. |
| Year(s) Of Engagement Activity | 2017 |
| Description | FAO/OIE PPR vaccine expert Group meeting |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Presentations were made on vaccine development including DIVA and stabilised PPR Vaccine. All the vaccine produced, some of the funding agencies including GALVMED, policy makers OIE and FAO have attended this meeting. The meeting was organised by FAO.PI Satya Parida had presented work on Development of DIVA vaccine for PPR and DIVA ELISAs which was appreciated by everybody. In proceedings the use of DIVA vaccines at the end phase of eradication has been encouraged. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited as PPR vaccine expert to vaccine producers meeting at Jordan, Amman-organised by OIE and FAO PPR secretariat-13.04.19-17.4.19, |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Invited as PPR vaccine expert to vaccine producers meeting at Jordan, Amman-organised by OIE and FAO PPR secretariat-13.04.19-17.4.19, |
| Year(s) Of Engagement Activity | 2019 |
| Description | Invited lead talk and Chairing brain sterming session on FMD vaccine and control at international conference at Hyderabad Organised by NIAB |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | 1.Invited lead talk on Epidemiology of PPR.2. Chairing brain sterming session on FMD vaccine and control at international conference on Infectious animal diseases at Hyderabad Organised by NIAB |
| Year(s) Of Engagement Activity | 2014 |
| Description | Invited talk on Efficacy FMD vaccine using TLR adjuvants at NVRQS, South Korea |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Satya Parida was invited to deliver a talk on FMD vaccine using TLR adjuvants. Since 2010 South Korea is facing FMD outbreak and preparing themselves to prepare their own FMD Vaccine. As we have identified TLR 3 is a good adjuvant for stimulating humoral and cell-mediated response I received sparked questions and discussion afterwards. Recently I have received queries for providing details about the adjuvants so that they can include this adjuvant to their vaccine. |
| Year(s) Of Engagement Activity | 2016 |
| Description | Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Postgraduate students |
| Results and Impact | Invited talk on Epidemiology and vaccine development using reverse genetics techniques at Institute of Life science, Bhubaneswar India delivered on 5th of Feb, 2018. Students and scientists were encouraged to take forward the approach for human disease and some request obtained to visit our lab at the Pirbright, Institute. |
| Year(s) Of Engagement Activity | 2018 |
| Description | Invited talk on new generation FMD vaccines at NIAB faculty |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | Delivered an invited talk on new generation FMD vaccines to inform the collaborator how TLR III adjuvant lingers the duration of immunity. The talk initiated sparking questions after the talk. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Invited talk to deliver at SEOC ( Spanish Vaterinary Society) and small ruminant research forum, Spain on threat of PPR to Euorope |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Due to recent spread of PPR in north Africa there is a threat of PPR to Europe. A clear discussion was made and an manuscript has been published on this talk in small ruminant journal. |
| Year(s) Of Engagement Activity | 2015 |
| Description | Joined as a FAO expert at Chiang Mai, Thailand for PPR and FMD control in SAARC region and delivered two invited talks- 16.06.19-23.06.19 |
| Form Of Engagement Activity | A magazine, newsletter or online publication |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | Joined as a FAO expert at Chiang Mai, Thailand for PPR and FMD control in SAARC region and delivered two invited talks on FMD and PPR Global situations- 16.06.19-23.06.19 |
| Year(s) Of Engagement Activity | 2019 |
| Description | Oral presentation at EUFMD meeting, Burgo, Italy on Longer duration of Immunity of FMD vaccine |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | Talk on duration immunity for FMD vaccine and how it can be double by adding a TLR3 adjuvant to the correct vaccine formulation. This sparked questions and discussion afterwards. vaccine industries were keen on this. |
| Year(s) Of Engagement Activity | 2018 |
| Description | PPR vaccine producers meeting at MCI, Morocco organised by FAO/OIE |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | PPR vaccine producers meeting at MCI, Morocco organised by FAO/OIE. Almost all PPR vaccine producers through out world joined this meeting. Satya Parida has presented a talk on vaccine development and transmission of PPR virus in North Africa. There was hues interest on the talk particularly the spread of PPR in North Africa and new vaccine development. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Poster presentation at EUFMD meeting at Burgo by the senior postc of the PI group on epitope prediction of serotype O FMD virus |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Industry/Business |
| Results and Impact | In this presentation we have shown 3 new epitopes of the FMD virus. An manuscript has been submitted for publication on this. |
| Year(s) Of Engagement Activity | 2018 |
| Description | The peste des petits ruminants virus (PPRV) Global Research and Expertise Network (GREN) meeting. Presented work on the future eradication of PPRV, 13-15.11.2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | The peste des petits ruminants virus (PPRV) Global Research and Expertise Network (GREN) meeting. Presented work on the future eradication of PPRV, 13-15.11.2019 |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://rr-asia.oie.int/wp-content/uploads/2020/06/200622_ppr-gren-2-nairobi-november-2019-final-com... |
| Description | Workshop at Hainan province |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Study participants or study members |
| Results and Impact | An workshop was organised by CAHEC at Hainan province and researchers from Pirbright Institute working on various diseases and researchers throughout China working on PPR and related diseases had joined.Talks were delivered by these researchers throughout the day. |
| Year(s) Of Engagement Activity | 2011 |
| Description | Yearly visit (n=4) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Study participants or study members |
| Results and Impact | PI Satya Parida has visited CAHEC in each year during the project tenure and discussed work with colleagues of CAHEC working on PPR. Couple of times senior postdoc from Pirbright laboratory visited CAHEC with PI for exchange of whole genome sequencing technique discussion. Similar visits have been made by CAHEC and LVRI scientists to the Pirbrght Institute. |
| Year(s) Of Engagement Activity | 2012,2013,2014,2015 |